Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 4, 2004 - Issue 2
Submit an article Journal homepage
31
Views
26
CrossRef citations to date
0
Altmetric
Review

Signature of a silent killer: expression profiling in epithelial ovarian cancer

Cécile Le Page Centre de recherche du Centre Hospitalier de l’Université de Montréal/Institut du cancer de Montréal, 1560, rue Sherbrooke est, Montreal, Quebec H2L 4M1, Canada. [email protected]
,
Diane Provencher Centre de recherche du Centre Hospitalier de l’Université de Montréal/Institut du cancer de Montréal, 1560, rue Sherbrooke est, Montreal, Quebec H2L 4M1, Canada. [email protected]
,
Christine M Maugard Centre de recherche du Centre Hospitalier de l’Université de Montréal/Institut du cancer de Montréal, 1560, rue Sherbrooke est, Montreal, Quebec H2L 4M1, Canada. [email protected]
,
Véronique Ouellet Centre de recherche du Centre Hospitalier de l’Université de Montréal/Institut du cancer de Montréal, 1560, rue Sherbrooke est, Montreal, Quebec H2L 4M1, Canada. [email protected]
&
Anne-Marie Mes-Masson Centre de recherche du Centre Hospitalier de l’Université de Montréal/Institut du cancer de Montréal, 1560, rue Sherbrooke est, Montreal, Quebec H2L 4M1, Canada. [email protected]
Pages 157-167 | Published online: 09 Jan 2014

References

  • Ozois RE Update on the management of ovarian cancer. Cancer 1 8(Suppl. 1), S22—S30 (2002).
  • Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 88(1 Pt 2), S8—S10 (2003).
  • Runnebaum TB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J. Cancer Res. Clin. Oncol 127(2), 73–79 (2001).
  • Russell AH. All, none or some? Gynecol Oncol 89(3), 341–342 (2003).
  • Serov SF, Scully R, Sobin LH. Histological typing of ovarian tumours. In: International 1-listological Classification of TUMOUTS, Volume 9. World Health Organization, Geneva, Switzerland (1973).
  • Chuaqui RF, Cole IKA, Emmert-Buck MR, Merino MJ. Histopathology and molecular biology of ovarian epithelial tumors. Ann. Diagn. Pallid 2(3), 195–207 (1998).
  • Crispens MA. Borderline ovarian tumors: a review of the recent literature. C1.117: Opin. Obstet. Gynecol 15(1), 39–43 (2003).
  • Modugno E Ovarian cancer and high-risk women: implications for prevention, screening and early detection. Gynecol Oncol 91(1), 15–31 (2003).
  • Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC Jr, Brewer MA. Specific keynote: chemoprevention of ovarian cancer: the journey begins. Gynecol Oncol 88(1 Pt 2), S59—S66 (2003).
  • Pfisterer J, Hilpert F, Du Bois A, Meier W, Wagner U. State-of-the-art first-line treatment of ovarian cancer. Onkologie 26(5), 446–450 (2003). itMarkman M. Consolidation/maintenance chemotherapy for ovarian cancer. Curn Oncol Rep. 5(6), 454–458 (2003).
  • Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7\(Suppl. 5), 20–28 (2002).
  • Muggia FM, Liebes L, Hazarika M eta]. Phase I and pharmacologic study of ip. 9-aminocamptothecin given as six fractions over 14 days. Anti Cancer Drugs 13(8), 819–825 (2002).
  • Chi DS, Liao JB, Leon LF et al Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82(3), 532–537 (2001).
  • Li AJ, Karlan BY. Surgical advances in the treatment of ovarian cancer. Hematol Oncol Clin. North Am. 17(4), 945–956 (2003).
  • Therasse P, Arbuck SG, Eisenhauer EA etal New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205–216 (2000).
  • Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin. North Am. 17(4), 957–968 (2003).
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Ce11100(1), 57–70 (2000).
  • Ahmed FE. Molecular techniques for studying gene expression in carcinogenesis. Environ. Li. Health Part C Environ. Catrinog. Ecotoxicol Rev. 20(2), 77–116 (2002).
  • Heller MJ. DNA microarray technology: devices, systems and applications. Ann. Rev Blamed Eng. 4,129–153 (2002).
  • Brazma A, Hingamp P, Quackenbush J etal Minimum information about a microarray experiment (MIAME): toward standards for microarray data. Nature Genet. 29(4), 365–371 (2001).
  • Slonim DK. From patterns to pathways: gene expression data analysis comes of age. Nature Genet. 32(Suppl.), 502–508 (2002).
  • Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Co-ordinately upregulated genes in ovarian cancer. Cancer Res. 61(10), 3869–3876 (2001).
  • ZOM KIK, Jazaeri AA, Awtrey CS eta]. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin. Cancer Res. 9(13), 4811–4818 (2003).
  • •Demonstrates the importance of the appropriate choice of normal controls used in gene expression analysis of ovarian cancer.
  • Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nature Biotechnol 18(4), 457–459 (2000).
  • Tonin PN, Hudson TJ, Rodier F eta]. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 20(45), 6617–6626 (2001).
  • Ismail RS, Baldwin RL, Fang J eta]. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 60(23), 6744–6749 (2000).
  • Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng. 83(2), 173–180 (2003).
  • Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao J, Chang DD. Gene expression in epithelial ovarian carcinoma. Oncogene 21(41), 6289–6298 (2002).
  • Ono K, Tanaka T, Tsunoda T etal Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 60(18), 5007–5011(2000).
  • Martoglio AM, Tom BD, Starkey M, Corps AN, Chamock-Jones DS, Smith SK. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mal Med. 6(9), 750–765 (2000).
  • Welsh JB, Zarrinkar PP, Sapinoso LM etal Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl Acad. Sc]. USA 98(3), 1176–1181 (2001).
  • Schummer M, Ng WV, Bumgarner RE etal Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238(2), 375–385 (1999).
  • Wong KIK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30 (3), 670–675 (2001) .
  • Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 22 (10), 1568–1579 (2003).
  • Hough CD, Sherman-Baust CA, Pizer ES etal Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60(22), 6281–6287 (2000).
  • Hedenfalk I, Ringner M, Ben-Dor A etal Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc. Natl Acad. Sc]. USA 100(5), 2532–2547 (2003).
  • Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET Gene expression profiles of BRCAl-linked, BRCA2-linked and sporadic ovarian cancers. Natl Cancer Inst. 94 (13), 990–1000 (2002).
  • Shi H, Wei SH, Leu YVV et al Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation and histone acetylation. Cancer Res. 63 (9), 2164–2171 (2003).
  • Golub TR, Slonim DK, Tamayo P etal, Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531–547 (1999).
  • ••Multiple tumor classification usingcorrelation metric algorithms in the analysis of DNA microarray profiles.
  • Ross DT, Scherf U, Eisen MB etal Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet. 24(3), 227–235 (2000).
  • Ramaswamy S, Tamayo P, Rifkin R etal Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sc]. USA 98(26), 15149–15454 (2001).
  • Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 62(10), 2923–2928 (2002).
  • Nishizuka S, Chen ST, Gwadry PG etal Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic and tissue array profiling. Cancer Res. 63 (17), 5243–5250 (2003).
  • Schwartz DR, Kardia SL, Shedden IKA etal Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 62(16), 4722–4729 (2002).
  • Schaner ME, Ross DT, Ciaravino G etal Gene expression patterns in ovarian carcinomas. Mal Biol. Cell 14(11), 4376–4386 (2003).
  • Rimessi P, Gualandi F, Morelli C et al Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene 9(12), 3467–3474 (1994).
  • Sandhu AK, Kaur GP, Reddy DE, Rane NS, Athwal RS. A gene on 6q 14–21 restores senescence to immortal ovarian tumor cells. Oncogene 12(2), 247–252 (1996).
  • Wan M, Sun T, Vyas R, Zheng J, Granada E, Dubeau L. Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2cM fragment in chromosomal region 6q24-q25. Oncogene 18(8), 1545–1551 (1999).
  • Bayani J, Brenton JD, Macgregor PP etal Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization and expression microarrays. Cancer Res. 62 (12), 3466–3476 (2002).
  • Manderson EN, Mes-Masson AM, Novak J etal Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res. 12 (1), 112–121 (2002).
  • •First microarray analysis correlating gene expression and chromosomal abnormalities in ovarian cancer.
  • Jazaeri AA, Lu K, Schmandt R etal Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mal Carrinog: 36(2), 53–59 (2003).
  • Hellstrom I, Raycraft J, Hayden-Ledbetter M etal The HE4 (VVFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63(13), 3695–3700 (2003).
  • Kim JH, Skates SJ, Uede T etal Osteopontin as a potential diagnostic biomarker for ovarian cancer. JA MA 287(13), 1671–1679 (2002).
  • Mok SC, Chao J, Skates S etal Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst. 93(19), 1458–1464 (2001).
  • ••Clinical relevance of a new ovarian cancermarker uncovered by microarray analysis.
  • Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology and prognostic factors. Semin. Surg. Oncol 19(1), 3–10 (2000).
  • van 't Veer LJ, Dai H, van de Vijver MJ etal Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530–536 (2002).
  • ••Application of gene expression profilingof 70 genes correlated with 5-year outcome as a predictive tool for metastatic breast cancer.
  • XU S, Mou H, Lu G etal Gene expression profile differences in high and low metastatic human ovarian cancer cell lines by gene chip. Chin. Medfl,g1.)115(1),36–41 (2002).
  • Yousef GM, Scorilas A, Katsaros D etal Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. Clin. Oncol 21(16), 3119–3126 (2003).
  • Obiezu CV, Scorilas A, Katsaros D etal Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res. 7(8), 2380–2386 (2001).
  • Kim H, Scorilas A, Katsaros D etal Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. Cancer84 (5), 643–650 (2001).
  • Shvartsman HS, Lu KH, Lee J et al Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Cynecol Oncol 90(1), 44–50 (2003).
  • Salvesen FIB, MacDonald N, Ryan A eta]. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. int. j Cancer 91(1), 22–26 (2001).
  • Okuda T, Otsuka J, Sekizawa A et al p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Cynecol Oncol 88(3), 318–325 (2003).
  • Wen WH, Bernstein L, Lescallett J etal Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res. 60(10), 2716–2722 (2000).
  • Shridhar V, Lee J, Pandita A etal Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 61(15), 5895–5904 (2001).
  • Makhija S, Sit A, Edwards R et al Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Cynecol Oncol 90(1), 3–9 (2003).
  • Aigner A, Hsieh SS, Malerczyk C, Czubayko E Reversal of HER-2 overexpression renders human ovarian cancer cells highly resistant to taxol. Toxicology144(1–3), 221–228 (2000).
  • Kamazawa S, Kigawa J, Kanamori Y etal Multi-drug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Cynecol Oncol 86(2), 171–176 (2002).
  • Sakamoto M, Kondo A, Kawasaki K etal Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum. Ce1114 (4), 305–315 (2001).
  • Taniguchi T, Tischkowitz M, Ameziane N etal Disruption of the Fanconi anemia: BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Merl 9(5), 568–574 (2003).
  • Sherman-Baust CA, Weeraratna AT, Rangel LB etal Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3 (4), 377–386 (2003) .
  • Lamendola DE, Duan Z, Yusuf RZ, Seiden MV Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res. 63(9), 2200–2205 (2003).
  • Wang K, Gan L, Jeffery E etal Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 229(1-2), 101–108 (1999).
  • Martoglio AM, Miskin JW, Smith SK etal A decomposition model to track gene expression signatures: preview on observer-independent classification of ovarian cancer. Bioinformatics 18 (12), 1617–1624. (2002).
  • Lancaster JM, Dressman HK, Whitaker RS etal Gene expression patterns that characterize advanced stage serous ovarian cancers.j Soc. Cynecol Inves4 11,51–59 (2004).

Websites

  • International Federation of Gynecology and Obstetrics www.figo.org (Viewed February 2004)
  • Minimum Information About a Microarray Experiment — MIAME www.mged.org/Workgroups/MIAME/ miame.html (Viewed February 2004)
  • SMD Microarray Links: Software & Tools http://genome- www5.stanford.edu/restech.shtml (Viewed February 2004)
  • Bioconductor project www.bioconductor.org (Viewed February 2004)
  • Packages For Gene Expression Analysis www.stat.uni-muenchen.de/%7Estrimmer/rexpress.html (Viewed February 2004)
  • Center for Genome Research: GeneCluster2 www.broad.mitedu/cancer/software/ genecluster2/gc2.html (Viewed February 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.